RESUMEN
OBJECTIVES: Little is known about the cardiotoxic effects of kratom (Mitragyna speciosa Korth.), a medicinal plant. This analytical cross-sectional study investigated the prevalence of electrocardiogram (ECG) abnormalities and QTc intervals in regular kratom users compared with non-kratom-using control subjects. METHODS: We enrolled regular kratom users and non-kratom-using control subjects from three communities. Demographic data, clinical data, kratom use characteristics, and ECG findings were recorded. The mitragynine content of kratom juice was quantified using a validated gas chromatography-mass spectrometry (GC-MS) method. RESULTS: A total of 200 participants (100 kratom users and 100 control subjects) participated in this study. The prevalence of ECG abnormalities in kratom users (28%) did not differ from that of control subjects (32%). Kratom use was not associated with ECG abnormalities, except for significantly higher odds of sinus tachycardia (OR = 8.61, 95% CI = 1.06-70.17, p = 0.035) among kratom users compared with control subjects. The odds of observing borderline QTc intervals were significantly higher for kratom users compared with control subjects, regardless of the age of first use, the duration of use, the daily quantity consumed, and the length of time that had elapsed between last kratom use and ECG assessment. Nevertheless, there were no differences in the odds of having prolonged QTc intervals between kratom users and controls. The estimated average daily intake of mitragynine consumed by kratom users was 434.28 mg. CONCLUSION: We found no link between regular kratom use and electrocardiographic abnormalities with an estimated average daily intake of 434.28 mg of mitragynine.
Asunto(s)
Cardiopatías Congénitas/inducido químicamente , Cardiopatías Congénitas/etiología , Mitragyna/efectos adversos , Mitragyna/química , Plantas Medicinales/efectos adversos , Alcaloides de Triptamina Secologanina/efectos adversos , Adulto , Anciano , Anciano de 80 o más Años , Estudios Transversales , Femenino , Voluntarios Sanos , Humanos , Malasia , Masculino , Persona de Mediana Edad , Extractos Vegetales/efectos adversos , Extractos Vegetales/química , Plantas Medicinales/químicaRESUMEN
Brain-derived neurotrophic factor (BDNF) is a neurotrophin that is highly expressed in the brain. It influences neuronal survival, growth and acts as a control centre for neurotransmitters. It also plays a crucial role in learning and memory. Current evidence indicates that BDNF may be a possible neurotrophic factor that controls cognitive functions under normal and neuropathological conditions. Recent findings indicate a reduction in cognitive performance in individuals with Alzheimer's disease (AD). This relationship between cognitive performance and AD is important for investigating both the time they overlap and the pathophysiological mechanism in each case. Therefore, this study reviewed the existing knowledge about BDNF and cognitive performance in the AD population. The findings support the idea that this tropic factor may be a potential biomarker for evaluating the changes in cognitive performance in AD.
Asunto(s)
Enfermedad de Alzheimer , Factor Neurotrófico Derivado del Encéfalo , Biomarcadores , Cognición , HumanosRESUMEN
Objectives: Posttraumatic growth (PTG) is the experience of positive psychological growth as a result of struggle with highly challenging life crises. This study was conducted to investigate the degree of PTG and its associated factors, as well as to identify which positive psychological parameters most significantly associated with greater PTG among Malaysian cancer patients. Design, sample, & methods: This cross-sectional survey included 195 patients with different cancer diagnoses. Perceived spousal support, level of hope, level of optimism, and PTG were measured using various validated indexes. Findings: The total mean score for PTG Inventory-Short Form (PTGI-SF) was 39.87 (±9.09). Female gender, Islamic religious belief, and having higher level of hope and greater spousal support were associated with a higher PTGI-SF score, and the most significant predictor was the hope scale. Conclusions: Malaysian cancer patients exhibited a high level of PTG, and hope was the positive psychological factor which was most significantly associated with PTG. Implications for psychosocial providers: Psychosocial interventions that promote positive psychology should be included in the treatment for cancer patients.
Asunto(s)
Neoplasias/psicología , Crecimiento Psicológico Postraumático , Adulto , Estudios Transversales , Femenino , Esperanza , Humanos , Malasia , Masculino , Persona de Mediana Edad , Neoplasias/diagnóstico , Neoplasias/terapiaRESUMEN
BACKGROUND: Positive and negative psychological reactions have been described in head and neck cancer patients. Nevertheless, the relationships between these responses across time need to be studied to understand the patients' strengths and vulnerabilities. OBJECTIVES: The aim of this study is to determine the changes in posttraumatic growth (PTG), depression and anxiety longitudinally and the correlations between PTG and depression and anxiety in head and neck cancer patients. METHODS: A prospective study was conducted on 60 head and neck cancer patients within a year of diagnosis recruited from an oncology referral centre in Malaysia with 50 patients completing the study. The PTG Inventory-Short Form (PTGI-SF) and Hospital Anxiety and Depression Scale (HADS) were used at baseline and at 6 months follow-up. RESULTS: There were significant reductions in the scores of PTGI-SF (mean difference = -5.5, p = 0.014), HADS (Depression) (mean difference = -2.0, p < 0.05) and HADS (Anxiety) (mean difference = -2.0, p < 0.05) from baseline to follow-up. However, their correlations were not significant. HADS (Depression) score at baseline showed weak inverse correlation with PTGI-SF score (rho = -0.147, p = 0.309), whereas PTGI-SF score had weak positive correlations with HADS (Anxiety) at baseline (rho = 0.261, p = 0.067), HADS (Depression) at follow-up (rho = 0.083, p = 0.566) and HADS (Anxiety) at follow-up (rho = 0.111, p = 0.445). HADS scores also did not predict total PTGI-SF score longitudinally. CONCLUSION: There were reductions in PTG, depression and anxiety within a year of cancer diagnosis and 6 months later with no significant correlations between PTG with depression and anxiety.